Carevive at ViVE 2023 Q+A

Carevive’s presence at the ViVE conference was marked by John Elliott, the VP of Sales, discussing their exciting initiatives and insights. With a focus on remote symptom pathways and standardizing responses to severe symptoms in oncology patients, Carevive’s commercial product garnered attention for its potential to optimize care team practices and address nurse staffing shortages. Looking ahead, John reflected on previous engagements at notable healthcare conferences and highlighted the ongoing conversations surrounding the enhancement of the oncology care model and the transition from the OCM model to a two-sided risk model. The anticipated outcomes and efficiencies to be captured under this new model and the valuable data collected will provide insights and learning opportunities for Carevive and the oncology community.

Showcasing Remote Symptom Pathways:

Carevive’s commercial product, developed on their electronic patient-reported outcomes platform, offers a standardized approach to managing symptoms in oncology patients. By considering patient diagnosis, demographics, treatment, and symptoms, care teams can provide appropriate responses, ensuring standardized and efficient care delivery. This system becomes particularly relevant in the current context of nurse staffing shortages, allowing care teams to practice at the top of their license and provide optimal care to patients.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…